Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
BUSINESS OF BIOTECHNOLOGY
They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.
Business of Biotechnology is part of Business Exchange, suggested by
Arlene Weintraub.
This topic contains
3,200 news
and
4,479 blog
items.
Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from
like-minded professionals.
Most Active
add content
The most active stories in this topic based on user activity.
Nov. 2 (Bloomberg) -- Takeda Pharmaceutical Co., maker of the world’s best-selling diabetes drug, agreed to pay as much...
From this week's Hedge Fund Solutions Catalyst Equity Research Report, we are highlighting the Biotechnology Value...
New York, NY (AHN) – Genomic researcher J. Craig Venter has been awarded The Economist magazine’s Innovation Award for...
Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy.
The drug giant suffers a setback in its effort to boost its oncology pipeline.
Talecris Biotherapeutics (TLCR) plans to go public this week. The biotech company is a maker of plasma-derived protein...
A new way of attacking the painful skin disease had received the green light from the FDA.
When VCs consider a biotech investment, they usually factor the direct costs of the studies they’re being asked to fund...
Pascal Soriot, the man charged with integrating Roche Holding AG (SWX:ROG) and Genentech Inc. -- alongside former...
Wall Street pored over new trial results for Amgen's anemia drug Aranesp on Aug. 26
When Arena Pharmaceuticals (Nasdaq: ARNA) released positive Phase III data on its obesity drug, Lorcaserin, many people...
Drugmakers may push for an overhaul of the U.S. health care system by spending $100 million on ads starting as early as...
According to this article in outsourcing-pharma.com Pfizer has teamed up with Private Access Team to boost trial...
Should a branded biotech get 5 years or 12 years of protection from generic competition?
A recent report issued by Scientific American, "Scientific American Worldview: A Global Biotechnology...
They say that nobody should start a company to make money. Here’s proof: for all the buzz about biotech, in 40 years...
Human Genome Sciences Inc shares rose nearly 12 percent on Tuesday on rumors that Glaxo may buy the long-struggling...
Companies are developing knee patches: small, off-the-shelf plugs engineered to the composition of human bone and...
Investors are eager for news on denosumab, which the FDA will be discussing soon.
I have remarkable news for you. It ranks, in fact, among the great humanitarian breakthroughs of our age. BioTime, Inc.
www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.
Groundbreaking cognitive neuroscience research has occurred over the last 20 years - without parallel growth of...
Biotech Stock News - Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline Announce Positive Phase 3 Study Results...
Top Sources: Business of Biotechnology
- contrarianprofits.com
- Forbes.com
- thestreet.com
- Health Beat
- industry.bnet.com
- news.bbc.co.uk
- investorideas.com
- Reuters
- frontendofinnovation.blogspot.com
- BusinessWeek
Post a Job
Jobs in this Topic
Associate Director / Director, Business Development
Portola Pharmaceuticals
|
South San Francisco, CA
Posted: Oct 9
